Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Condition:   Sickle Cell Disease
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Bone Marrow Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute;   National Marrow Donor Program
Recruiting - verified February 2017